In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocytic Leukemia. Top experts provide in-depth perspectives on CLL, including basic biology, frontline and relapsed refractory treatments, mechanisms of resistance to targeted therapies, Richter’s transformation, and some of the common complications of the disease stemming from immune dysfunction—offering a state-of-the-art overview of the field to help optimize the care of patients with CLL.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia - p. 845 9. The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity - p. 859 10. Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s Tyrosine Kinase Inhibitors: A Comprehensive Overview - p. 875 11. First-line Therapy: Time-Limited Venetoclax Doublet Therapy - p. 885 12. Triplet Therapies in Chronic Lymphocytic Leukemia - p. 903 13. Measurable/Minimal Residual Disease: What Method and What Cut-Off? - p. 917 14. Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia - p. 935 15. Resistance to Bruton Tyrosine Kinase Inhibitors - p. 951 16. Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia - p. 965 17. Immunotherapy in Chronic Lymphocytic Leukemia - p. 981 18. Advances in the Understanding of Richter Transformation - p. 997 19. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia - p. 1013 20. Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia - p. 1031
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocytic Leukemia. Top experts provide in-depth perspectives on CLL, including basic biology, frontline and relapsed refractory treatments, mechanisms of resistance to targeted therapies, Richter’s transformation, and some of the common complications of the disease stemming from immune dysfunction—offering a state-of-the-art overview of the field to help optimize the care of patients with CLL.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia - p. 845 9. The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity - p. 859 10. Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s Tyrosine Kinase Inhibitors: A Comprehensive Overview - p. 875 11. First-line Therapy: Time-Limited Venetoclax Doublet Therapy - p. 885 12. Triplet Therapies in Chronic Lymphocytic Leukemia - p. 903 13. Measurable/Minimal Residual Disease: What Method and What Cut-Off? - p. 917 14. Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia - p. 935 15. Resistance to Bruton Tyrosine Kinase Inhibitors - p. 951 16. Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia - p. 965 17. Immunotherapy in Chronic Lymphocytic Leukemia - p. 981 18. Advances in the Understanding of Richter Transformation - p. 997 19. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia - p. 1013 20. Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia - p. 1031
